Patient characteristics
Characteristic . | No mutation, no. . | CFH mutation, no. . | MCP mutation, no. . | IF mutation, no. . | P1 . | P2 . | P3 . |
|---|---|---|---|---|---|---|---|
| Disease onset | |||||||
| Childhood, younger than 18 y | 52 (86) | 30 (42) | 10 (14) | 3 (6) | .22 | .43 | > .999 |
| Adulthood, 18 y or older | 34 (86) | 12 (42) | 4 (14) | 3 (6) | .22 | .43 | > .999 |
| Triggers | |||||||
| Pregnancy | 6 (66) | 1 (26) | 0 (12) | 2 (5) | .39 | .28 | .49 |
| Drugs | 4 (66) | 1 (26) | 0 (12) | None | .67 | .38 | .49 |
| Flulike, gastroenteritis, other infections | 46 (66) | 18 (26) | 12 (12) | 3 (5) | .96 | .03 | .03 |
| No triggers | 1 (66) | 1 (26) | 0 (12) | None | NA | NA | NA |
| Other triggers | 10 (66) | 5 (26) | 0 (12) | None | .63 | .15 | .10 |
| Recurrences | 30 (84) | 15 (42) | 9 (14) | 2 (6) | > .999 | .04 | .06 |
| Biochemical evaluation | |||||||
| Reduced C3 serum levels, 83 mg/dL or less* | 22 (71) | 16 (31) | 4 (12) | 3 (5) | .047 | .87 | .28 |
| Reduced C4 serum levels, 15 mg/dL or less* | 6 (69) | 1 (29) | 0 (12) | 0 (4) | .36 | .29 | .51 |
| Reduced CFH serum levels, 350 mg/L or less† | 1 (73) | 5 (34) | 0 (12) | 0 (5) | .005 | .68 | .16 |
| Reduced IF serum levels, below 70%‡ | 0 (57) | 0 (23) | 0 (10) | 0 (3) | NA | NA | NA |
Characteristic . | No mutation, no. . | CFH mutation, no. . | MCP mutation, no. . | IF mutation, no. . | P1 . | P2 . | P3 . |
|---|---|---|---|---|---|---|---|
| Disease onset | |||||||
| Childhood, younger than 18 y | 52 (86) | 30 (42) | 10 (14) | 3 (6) | .22 | .43 | > .999 |
| Adulthood, 18 y or older | 34 (86) | 12 (42) | 4 (14) | 3 (6) | .22 | .43 | > .999 |
| Triggers | |||||||
| Pregnancy | 6 (66) | 1 (26) | 0 (12) | 2 (5) | .39 | .28 | .49 |
| Drugs | 4 (66) | 1 (26) | 0 (12) | None | .67 | .38 | .49 |
| Flulike, gastroenteritis, other infections | 46 (66) | 18 (26) | 12 (12) | 3 (5) | .96 | .03 | .03 |
| No triggers | 1 (66) | 1 (26) | 0 (12) | None | NA | NA | NA |
| Other triggers | 10 (66) | 5 (26) | 0 (12) | None | .63 | .15 | .10 |
| Recurrences | 30 (84) | 15 (42) | 9 (14) | 2 (6) | > .999 | .04 | .06 |
| Biochemical evaluation | |||||||
| Reduced C3 serum levels, 83 mg/dL or less* | 22 (71) | 16 (31) | 4 (12) | 3 (5) | .047 | .87 | .28 |
| Reduced C4 serum levels, 15 mg/dL or less* | 6 (69) | 1 (29) | 0 (12) | 0 (4) | .36 | .29 | .51 |
| Reduced CFH serum levels, 350 mg/L or less† | 1 (73) | 5 (34) | 0 (12) | 0 (5) | .005 | .68 | .16 |
| Reduced IF serum levels, below 70%‡ | 0 (57) | 0 (23) | 0 (10) | 0 (3) | NA | NA | NA |
IF mutation group has not been included in statistical analysis. The numbers of patients for whom data were available are reported in parentheses. Significant P values are in italics.
P1 indicates no mutation versus CFH mutation; P2, no mutation versus MCP mutation; P3, CFH mutation versus MCP mutation; and NA, not applicable.
C3 and C4 levels were measured by kinetic nephelometry.
CFH serum levels were measured by radial immunodiffusion assay.
IF serum levels were measured by ELISA.